EMRELIS® (Telisotuzumab vedotin-tllv)

The FDA on May 14, 2025, granted accelerated approval to EMRELIS®, a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous Non-Small Cell Lung Cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. EMRELIS® is a product of AbbVie Inc.